Lucinda Billingham

University of Birmingham - Cancer Research Clinical Trials Unit
Professor of Biostatistics

Lucinda Billingham BSc MSc PhD CStat
Lucinda Billingham is Professor of Biostatistics within the Institute of Cancer and Genomic Sciences at the University of Birmingham. She has worked for over twenty years as a Biostatistician at their Cancer Research UK Clinical Trials Unit and is now Director of Biostatistics for the Unit working with a large team of Biostatisticians on an extensive portfolio of early and late phase trials. Lucinda has a special interest in lung cancer research and is the Chief Biostatistician for the National Lung Matrix Trial. She is a member of the British Thoracic Oncology Group Steering Committee and is an invited member of the Cancer Research UK Clinical Expert Review Panel providing statistical advice for funding applications. She lectures on a number of undergraduate and postgraduate courses at Birmingham, teaches widely on external courses and provides PhD supervision.

dont miss

National Lung Matrix Trial: testing multiple novel targeted treatments

The National Lung Matrix Trial (NLMT) is a flagship trial in the United Kingdom being the first to combine the development of a technology platform that screens for multiple genetic aberrations in lung tumours (provided by the Cancer Research UK Stratified Medicine Programme) with testing of multiple novel genetic-marker-directed drugs. This presentation will summarise the challenges encountered with design, implementation and reporting of this umbrella-basket phase II platform trial.

EVEN MORE SEMINARS

  • MR. KELVIN K.W LAU: Speaking at the Oncology Convention

    MR. KELVIN K.W LAU
    Barts Health NHS Trust

    IMAGE GUIDANCE FOR BRONCHOSCOPY AND LUNG SURGERY

  • Professor Noel Clarke: Speaking at the Oncology Convention

    Professor Noel Clarke
    The Christie and Salford Royal Hospitals, Manchester UK

    Improving Prostate Cancer Outcomes Through Cancer Trials

  • Dr. Henrik Harling: Speaking at the Oncology Convention

    Dr. Henrik Harling
    2cureX

    IndiTreat® functional profiling, to match effective cancer drug treatment to individual cancer patients

  • Dr Paul Fenton: Speaking at the Oncology Convention

    Dr Paul Fenton
    University Hospital Southampton NHS Foundation Trust

    Rapid Access Multidisciplinary Palliative Assessment and Radiotherapy Treatment (RAMPART) clinic

  • Louisa Davies: Speaking at the Oncology Convention

    Louisa Davies
    University College Hospital

    Is cancer crowdfunding fuelling quackery